These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3094926)

  • 1. Monitoring and avoiding drug and chemical teratogenicity.
    Koren G; MacLeod SM
    CMAJ; 1986 Nov; 135(10):1079-81. PubMed ID: 3094926
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacovigilance and practical medicine. Pragmatic approach in therapeutic counseling for pregnant women].
    Demarez JP; Bégaud B
    Therapie; 1987; 42(2):223-6. PubMed ID: 3616999
    [No Abstract]   [Full Text] [Related]  

  • 3. Methods for judging human teratogenicity.
    Fabro S; Brent RL; Clayson D; Palmer AK; Jebinek LR; Krupp P; Leonov B; Lippman A; Schardein JL; Sever JL
    Prog Clin Biol Res; 1985; 163C():177-80. PubMed ID: 3991620
    [No Abstract]   [Full Text] [Related]  

  • 4. Methods of evaluating the alleged teratogenicity of environmental agents.
    Brent RL
    Prog Clin Biol Res; 1985; 163C():191-5. PubMed ID: 3991621
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating the alleged teratogenicity of environmental agents.
    Brent RL
    Clin Perinatol; 1986 Sep; 13(3):609-13. PubMed ID: 3769377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment of drug use in pregnancy: prevention of birth defects.
    Peters PW
    Ann Ist Super Sanita; 1993; 29(1):131-7. PubMed ID: 8129259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mammalian models in teratology.
    Palmer AK
    Prog Clin Biol Res; 1985; 163A():97-106. PubMed ID: 3969396
    [No Abstract]   [Full Text] [Related]  

  • 8. Postmarketing surveillance for human teratogenicity: a model approach.
    Chambers CD; Braddock SR; Briggs GG; Einarson A; Johnson YR; Miller RK; Polifka JE; Robinson LK; Stepanuk K; Lyons Jones K
    Teratology; 2001 Nov; 64(5):252-61. PubMed ID: 11745831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of drugs in pregnancy and during lactation.
    Hawkins DF
    Proc Annu Symp Eugen Soc; 1981; 16():135-63. PubMed ID: 7346832
    [No Abstract]   [Full Text] [Related]  

  • 11. Postmarketing surveillance for drug safety in pregnancy: the Organization of Teratology Information Services project.
    Felix RJ; Jones KL; Johnson KA; McCloskey CA; Chambers CD;
    Birth Defects Res A Clin Mol Teratol; 2004 Dec; 70(12):944-7. PubMed ID: 15570610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for predicting human birth defects.
    Clayson DB
    Prog Clin Biol Res; 1985; 163C():197-203. PubMed ID: 3991622
    [No Abstract]   [Full Text] [Related]  

  • 13. Post-marketing evaluation of fertility-regulating drugs, as viewed by regulatory authorities.
    Hum Reprod; 1987 Jan; 2(1):45-58. PubMed ID: 3571447
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug treatment in the perinatal period and the risk of functional teratogenicity.
    Benesová O
    Arch Toxicol Suppl; 1996; 18():89-96. PubMed ID: 8678824
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recommendations for general drug therapy during pregnancy].
    Hüter J
    Z Allgemeinmed; 1973 Apr; 49(11):519-21. PubMed ID: 4705890
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
    Goujard J
    Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools.
    Uhl K; Trontell A; Kennedy D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):337-48. PubMed ID: 16953517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protecting the unborn: Dow's experience.
    Rao KS; Schwetz BA
    Occup Health Saf; 1981 Mar; 50(3):53-6, 58-61. PubMed ID: 6782529
    [No Abstract]   [Full Text] [Related]  

  • 19. Motherisk--a new approach to antenatal counselling of drug/chemical exposure.
    Koren G; Feldman Y; Shear N
    Vet Hum Toxicol; 1986 Dec; 28(6):563-5. PubMed ID: 3788043
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation.
    Yerby MS
    Epilepsia; 2003; 44 Suppl 3():33-40. PubMed ID: 12790884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.